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Germ-cell tumours (GCTs) are collectively the most common
cancer type in men aged 15–40 years, and they are a significant
cause of morbidity and mortality in this population. Platinum-
based chemotherapy has dramatically improved the outcome for
patients with metastatic disease since the first patient was treated at
Indiana University in 1974 (Einhorn & Donohue, 1977); however,
despite the high cure rate of 70–80%, B20–30% of patients with
metastatic disease will relapse after first-line chemotherapy
(Albany et al, 2017a). The International Germ-Cell Cancer
Collaborative Group (IGCCCG) classifies patients with metastatic
GCT into good, intermediate, and poor risk groups based on three
clinical prognostic criteria: primary tumour site, metastatic sites,
and the amplitude of serum tumour marker levels (IGCCCG,
1997). However, these IGCCCG prognostic criteria are merely a
reflection of the volume of disease rather than the pathology.
Currently, no biological prognostic serum biomarker exists for this
disease beyond the serum tumour markers alpha-fetoprotein (AFP)
and beta-subunit of human chorionic gonadotropin (hCG), and
these two markers do not predict who will relapse after
chemotherapy. For example, patients with elevated AFP
(410 000 ng/ml) or hCG (450 000 IU/L) are classified as poor-
risk, with a 50% chance of cure following four cycles of bleomycin,
etoposide and platinum (BEP) chemotherapy; however, we cannot
predict whether a particular patient will respond to this
chemotherapy. Thus, a biologically driven biomarker that reflects
the pathogenesis is highly needed.
Recent studies have demonstrated the role of tumour micro-
environmental inflammation in the proliferation and survival of
malignant cells, angiogenesis, metastasis, subversion of adaptive
immunity, and reduced response to chemotherapeutic agents;
making inflammation one of the hallmarks of cancer (Hanahan &
Weinberg, 2011). The systemic immune-inflammation index (SII),
which uses a simple calculation based on peripheral lymphocyte,
neutrophil, and platelet counts, was recently investigated as a
prognostic marker in several tumours (van Soest et al, 2015; Bhindi
et al, 2016; Lolli et al, 2016). In this issue of the British Journal of
Cancer, two articles highlight for the first time the prognostic
significance of SII in patients with GCT. Fankhauser et al (2018)
evaluated the prognostic value of SII in patients with metastatic
GCT treated with cisplatin-based chemotherapy. The neutrophil-
to-lymphocyte ratio (NLR) was also calculated. NLR and SII were
both independent predictors in a multivariable model of overall
survival (OS) when tested separately against the IGCCCG risk
classification.
Chovanec et al (2018) performed an interesting analysis,
whereby they combined SII and the prognostic significance of
PD-L1 expression on tumour infiltrating lymphocytes (TILs).
These two measurements reflect different aspects of the immune
environment; PD-L1’s expression on TILs provides an insight into
the tumour microenvironment, and SII indicates a global
inflammatory status. The high expression of PD-L1 on TILs is a
marker of T-cell exhaustion and could result in a reduced
proinflammatory environment. It is currently unclear whether
these two factors have a mechanistic connection; however,
combining the two allowed the identification of a new subgroup
of patients. Patients who showed high PD-L1 expression on TILs
and low SII exhibited the best prognosis, with 100% cure rate and
no relapses after chemotherapy. This is indeed a rare finding in the
literature on GCTs.
In this era of targeted treatment for solid tumours, there is a lack
of biomarkers for clinical management and therapeutic guidance in
refractory GCT. Multiple clinical trials utilising targeted therapy in
refractory GCT were disappointing, with individual patients only
rarely achieving objective responses with brentuximab vedotin
(Oing et al, 2016; Albany et al, 2017b). In part, this could be
explained by the lack of clinically validated biomarkers and the
molecular selection of patients prior to their enrolment in clinical
trials (Kollmannsberger et al, 2017). MicroRNAs (miRNAs) have
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more recently surfaced as a potential biomarker in monitoring
testicular cancer, with higher sensitivity and specificity when
compared with AFP and hCG (Dieckmann et al, 2017); however,
miRNAs are not prognostic and do not guide therapeutic decision.
Refining the prognosis of GCTs may begin with the newly
emerged biomarkers highlighted in these two papers, such as the
effect of PD-L1 on TILs and the SII. These novel GCT biomarkers
could represent a substantial step forward after the lengthy period
of stagnation in the understanding of GCT biology, and may
hopefully open the door for the future discovery of biomarker-
driven treatments. A key and significant premise of the two papers
is their focus on SII as a prognostic biomarker, which has the
potential to be readily adopted into the clinic, as it only requires a
simple complete blood count (CBC). If prospectively validated, this
could be a powerful yet simple tool to predict prognosis beyond the
historical IGCCCG guidelines. Looking forwards, it will also be
essential to look at whether SII is predictive for response to
chemotherapy, especially in patients with poor-risk disease.
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